InhA
InhAby Kelly Hrywkiw ContentsIntroductionThe enzyme InhA is coded from the INHA gene that is similar in sequence to the Salmonella typhimurium gene which plays a role in fatty acid synthesis, and is part of a short chain dehydrogenase/reductase family[1][2]. Inha is an NADH dependent trans enoyl-acyl ACP carrier protein that is part of the fatty acid biosynthesis system: fatty acid synthase two (FASII), and plays a role in the synthesis of Mycolic Acid[3][2]. Mycolic acids are long chain fatty acids (C54 to C63) that are essential in cell wall formation of the human pathogen Mycobacterium tuberculosisas well as other mycobateria such as Mycobacterium leprae, and are associated with virulence[4]. InhA has been proposed as the target of the thioamide drugs, ethionamide (ETH) and protionamide (PTH), which have been used in treatment of mycobacterial infections [2]. However stains of M. tuberculosis that are resistant to thioamide drugs have been increaseing worldwide, and therefor research into the exact mechanisms of these drugs is of importance.
Structure of InhAMomomeric subunit of InhA with bound EAD  The InhA enzyme of M. tuberculosis is a homotetramer (Fig. 1) composed of a repeating subunit of a single domain with a Rossmann Fold in the core that provides a NADH binding site[5]. The single domain can be broken down into two substructures that are connected by short peptide loop[1][5]. The overall structure exhibits α/β folding with a series of α helices flanking a central β sheet of multiple parallel β strands[5]. Substructure 1 of InhASubstructure 1 consists of 6 parallel β strands and 4 α helices interwoven together to form a core α/β structure that contains the n-terminal domain[1]. The first substructure can be further broken down into two sections, the first section consisting of two β strands (B-1 and B-2) and two short α helices (A-1 and A-2)[1]. The first section is connected to the second section by a β strand (B-3) that crosses over the two domains, and leads into the second section initiating at the third α helix (A-3)[1]. (A-3) is connected by a long loop to a 14 residue β strand (B-4) that then leads into the fourth α helix (A-4)[1]. A-4 then leads into a fifth strand β (B-5), followed by a 25 residue α helix (A-5), and into the final strand β (B-6)[1]. Substructure 2 of InhASubstructure 2 contains the c-terminal region of the molecule and consists of a small β strand (B-7), and two α helices (A-6 and A-7) which are connected by a short five residue loop[1]. The C-terminal domain consits of two other α helices (A-8 and A-9)[1]. Hydrophobic Binding PocketInhA contains a hydrophobic pocket where ligands bind to a higly conserved binding site[3]. The site is lined with the hydrophobic residues tyrosine 158 (Y158), phenylalanine 149 (F149) methionine 199 (M199), trypotophan 222 (W222), leucine 218 (K218), methionine 161 (M161), and proline 193 (P193)[3]. The fatty acyl binding site is also located in the hydrophobic pocket of InhA and consists primairly of the substrate binding loop (residues 196-219)[6].
InhA's Function in the Mycolic Acid Pathway InhA plays a key role in the synthesis of fatty acids, particularly in M. tuberculosis which, has type one fatty acid synthesis (FASI) and type two fatty acid synthesis (FASII) which together function in the synthesis of mycolic acids[8]. FASI synthesizes C16-18 and C24-26 fatty acids. The fatty acids from FASI are then sent to FASII which promotes chain extension, forming long-chain meromycolic acids that are 56-64 carbons in length[9]. The final step in FASII is completed by InhA which reduces 2-trans-enoyl-ACP's with chain lengths over twelve carbons in a NADP dependent manner where the hydride transfer precedes protonation(Fig. 2)[8][10]. The reaction takes place as follows: initially NADH binds to the active site mediated by van der Waal interactions with the side chains of phenylalanine 41 (F41), leucine 218 and methionine 155 (K218 and M155) to the phosphate group of NADH. There are additional interaction with lysine 165 (K165) that also mediate binding[10][5]. Binding of NADH causes a conformational change in the Aspartate 42 and Arginine 43 (E42 and R43) side chains and an over all conformational change in InhA[5][3]. In addition tyrosine 158 (Y158) plays an important role in aligning the carbonyl substrate, in fact; rotation about its Cα-Cβ bond by 60° brings it into a position where it can hydrogen bond to the carbonyl of the 2-trans enoyl-ACP and provide it with electrophilic stabilization[10]. The substrate binds in a U-shaped conformation with its trans double bond adjacent to the nicotinamide ring of NADH[6]. Inha then reduces the 2-trans double bond of the substrate by forming a enoyl intermediate through the transfer of a hydride ion from NADH to the third carbon of the substrate, followed by protonation of the second carbon[5]. The binding of both the substrate and the cofactor induces another conformational change in InhA that allows for the release of the meromycolic acid product[5]. The meromycolic acids undergo claisen condensation with a C26 fatty acid followed by reduction to a mature mycolic acid[9][5].
InhA and Thioamide Drugs The primary target of the thioamide drugs PTH and ETH have been shown to be InhA (go to original scene) in both genetic and molecular experiments[3]. Both PTH and ETH require activation by various cellular componets to form the NAD adduct that acts to inhibit InhA, and therefore connot be studied in in vitro[3]. The exacct mechanism of their activation is still under speculation, however a flavin monooxygenase (EthA) has been shown to participate in ETH and PTH activation[3]. In fact, strains of M. tuberculosis that have mutations in the gene which express EthA exhibit resistance to thioamide drugs[3]. Currently studies are being carried out to determine other methods of treatment for mycobaterial infections that dont require activation by cellular constituents, due to the incerease of drug resistant cases world wide. The ETH-NAD adduct (EAD) and the PTH-NAD adduct (P1H) have been found to occupy the same hydrophobic pocket of InhA as NADH and exhibit the same van der Waal interactions between (K218 and M155) and the ethyl or proply group with distances of 3.3Å and 3.2Å respectively[3]. EAD or P1H binding forces the rotation of F149 by 90° which causes a ring stacking interation with the pyridine ring on the adduct. In addtion π stacking interactions form between the propyl group of P1H and the ethyl group of EAD with Y158 at distance of ~3.3Å. These interations and conformational changes in InhA contribute to its inactivation. Developmentaly this is important, for InhA is no longer active an the mycolic acids nessasary in cell wall compostion of various mycobacteria will not be formed.
Protein SuperfamilyInhA can be categorized into two distinct families, SDR's and ACP's. The SDR FamilyInhA can also be classified into a family of short chain dehydrogenase/reductases (SDR's). This family consists of proteins exhibiting a central core with a Rossmann fold that contains a NADH binding site. There are approximately 3000 primary structures outlines in various sequence databases[11]. Examples of proteins in this family are listed below with links to their corresponding proteopedia page.
The ACP familyInhA can be further classified into the acyl carrier protein family(ACP's). These proteins generally all function in the transport of substrates in a myriad of pathways, such as: the synthesis of polypeptides and fatty acids[12].
| ||||||||||||
3D structures of ACP family
Additional Resources
- Mycobacterium tuberculosis InhA bound with ETH-NAD adduct, in the RCSB Protein Data Bank
- Mycobacterium tuberculosis InhA bound with PTH-NAD adduct, in the RCSB Protein Data Bank
- Crystal structure of wild-type InhA:NADH complex, in the RCSB Protein Data Bank
